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ABSTRACT
Purpose To investigate the effect of cryogrinding on chemical
stability of the diuretic agent furosemide and its mixtures with
selected excipients.
Methods Furosemide was ground at liquid nitrogen tempera-
ture for 30, 60, 120 and 180 min. Mixtures of furosemide-PVP
and furosemide-inulin (1:1) were milled under cryogenic con-
ditions. Materials were analyzed by XRD, UPLC, MS and NMR.
Results Upon increasing the milling time, a significant build-up
of an unidentified impurity 1, probably the main degradation
product, was noticed. Cogrinding of furosemide with PVP and
inulin worsened chemical stabilization of the pharmaceutical.
The main degradation product formed upon cryomilling was
subsequently identified as 4-chloro-5-sulfamoylanthranilic acid
(CSA). Based on some theoretical considerations involving
specific milling conditions, the milling intensity and an expected
specific milling dose have been calculated. Results indicate that
cryogenic grinding is capable to initiate mechanically induced
decomposition of furosemide.
Conclusions Cryogenic grinding can activate and accelerate
not only structural changes (solid state amorphization) but also
chemical decomposition of pharmaceuticals. A cryogenic
milling device should be considered as a chemical reactor,
where under favourable conditions chemical reactions could be
mechanically initiated.
KEY WORDS amorphous pharmaceuticals . cryogenic
grinding . furosemide . mechnochemical reactions . solid state
amorphization
INTRODUCTION
According to Biopharmaceutical Classification System
(BCS), pharmaceutically important particles are divided
into four categories on the basis of aqueous solubility and
permeability via oral route of delivery (1). Because of low
solubility and permeability, Active Pharmaceutical Ingre-
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dients (APIs) belonging to the last category (i.e. IV class) are
likely to exhibit low bioavailability and are still the most
challenging molecules for the modern pharmaceutical
industry. One of the most promising ways to tackle the
problem of insufficient dissolution rate of poorly water-
soluble drugs is particle size reduction. As shown in the
literature, micronization generally leads to improvement of
dissolution properties of drugs through increase in surface
area of micro- or nano-substances (2). A variety of methods
are used for producing drugs with reduced particle size.
However, micronization of drugs is frequently attempted
through extended mechanical milling.
Mechanical treatment of crystalline solids in a mill
(known also as grinding) is a very popular technique
applied in many fields of industry to reduce particle size.
The large amount of mechanical perturbations generated
during milling may result in significant changes in the
structure of the grinded material, including polymorphic
transformations, crystal defects and partial or complete
amorphization (3,4). In the latter case, complete transfor-
mation from crystal to amorphous state occurs only if the
grinding process takes place at a temperature much lower
than the glass transition temperature, Tg, of an equivalent
supercooled liquid.
Amorphous drugs offer a very interesting perspective for
pharmacy, basically because they are markedly more
soluble and dissolve faster as compared to their crystalline
counterparts (5). Nevertheless, one should still remember
that an amorphous solid is in the state of non-equilibrium
and sooner or later will revert to a more stable crystalline
state (6). Moreover, many studies have revealed that
enhanced chemical reactivity of amorphous pharmaceut-
icals related to molecular mobility speeds up their chemical
degradation (7).
Solid state amorphization via grinding has extensively
been studied for a long time. This research is concerned
mainly with metallic systems and inorganic compounds (8).
However, in recent years a lot of effort has been taken by
the Decamps group to put some insight into crystal-glass
transformation induced by milling in organic materials,
especially in the food and pharmaceuticals areas (9–11).
It is generally claimed that physical stability of amor-
phous drugs prepared by grinding of crystalline solids is
reduced as compared to that obtained by quenching of
liquid. For instance, glassy state of indomethacin obtained
by very slow cooling of the liquid is stable against
crystallization for over 2 years (12), but amorphous state
of IMC obtained by grinding is less stable and recrystallizes
to 90% after approximately 13–15 h (13). Certainly, the
changes which appear during grinding can affect the
stability and other physical properties of outcome material.
Thus, a better understanding of the nature of the crystal-to-
amorphous transformation seems to be fundamental.
In the literature there are several concepts for elucida-
tion of the crystalline-amorphous state transformation
induced by milling. For example, it has been suggested
that during mechanical impact, a certain amount of
mechanical energy is liberated. This can cause a local
heating effect resulting in local melting of the sample
followed by fast quenching. However, as demonstrated a
few years ago, no significant increase in temperature upon
milling occurred (10,11). The next scenario is based on the
Lindemann melting criterion stating that the crystalline-
amorphous solid transformation can simply be explained in
terms of melting of critically disordered crystals at temper-
atures below the glass transition point where the super-
cooled liquid exists in a configurationally-frozen state
(glassy state) (14). On the other hand, some researchers
have suggested that the solid-state amorphization occurs as
the result of softening of the crystalline lattice vibrations,
leading in a consequence to its collapse, while others claim
that during milling progressive lattice defects give rise to the
energy of the system. This provides essential thermody-
namic-driven force to begin transformation (15). It is also
worth keeping in mind that in the Martin and Bellon’s
‘driven material concept’ approach, the whole transforma-
tion involves competition between thermally independent
disordering process induced by milling and thermally
depending restoration process (16).
Grinding, as a non-conventional way of amorphization,
is a great alternative for the commonly used supercooling of
the molten crystal. This method is especially important with
compounds undergoing thermal degradation at the melting
point. It is thus impossible to prepare amorphous state by
quenching a liquid. It is also very suitable when a material
has a strong sensitivity to solvents and consequently there is
a big problem associated with selection of the solvent for
the freeze- and spray-drying technique, or when it is
necessary to prepare a pure amorphous API without
additional excipients, not dispersed molecularly in any
polymeric matrix.
Grinding of various types of crystalline materials can be
carried out using two options: 1) at room temperature in a
traditional ball mill or 2) in a cryogenic impact mill
immersed in liquid nitrogen (so-called cryogrinding, cry-
omilling). Recently, cryogrinding of pharmaceuticals has
attracted much attention (13,17,18). As it turns out, this
method is more efficient to prepare the glassy drugs than
the ball milling, since the material is completely frozen
during grinding. It is also believed that chemical degrada-
tion does not occur in this case, because the liquid nitrogen
temperature should prevent local temperature warm-up. It
is worth noting that until now there have been no precise
studies concerning drug decomposition upon cryomilling. A
few years ago, Graeser et al. reported on a lowered chemical
stability of simvastatin during cryomilling; however, the
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authors suggested that this effect was related to the
preparation method rather than to degradation (19).
The aim of this study is to examine the effect of
cryogrinding on the physical and chemical stability of the
popular diuretic agent, furosemide. The crystalline furose-
mide is sparingly soluble in aqueous systems, especially the
acidic ones. Experimental water solubility of crystalline
furosemide (0.006 mg/mL (20)) as well as its bioavailability
(20–60% (21)) allow for classifying the drug as a class IV
compound in BCS. From the literature it is also known that
furosemide appears to be very unstable at lower pHs and
undergoes hydrolysis and photochemical degradation in
aqueous solution (22). Moreover, it decomposes at a
melting point (Tm=206°C) (23). Consequently, it is
impossible to prepare its amorphous form in a conventional
way. For this reason, furosemide appeared to be one of the
challenging molecules for pharmaceuticals researchers. In
the past, some attempts had been made to improve its
stability in aqueous systems as well as its dissolution profile
(24,25). For example, a remarkable enhancement of the
dissolution rate was reported for a solid dispersion of
furosemide-PVP (26) or for ball milling of furosemide with
crospovidone (27). Interestingly, previous researchers didn’t
report about any signs of degradation of the drug caused by
milling.
In this study, we have tested the effect of cryogrinding of
pure furosemide on its stability. The samples cryomilled for
30, 60, 120 and 180 min were then analyzed with the use of
several techniques, namely X-Ray Powder Diffraction
(XRD), Mass Spectrometry (MS), Nuclear Magnetic Res-
onance (NMR) and Ultra-Performance Liquid Chromatog-
raphy (UPLC). The latter is known to be the most sensitive
analytical method, allowing detection of any trace impurity.
As will be shown in this paper, the milling of furosemide in
liquid nitrogen is actually not such a safe method of solid-
state amorphization as expected. Briefly, our result leads to
the conclusion that during cryomilling (milling carried out
at a liquid nitrogen temperature) chemical degradation of
furosemide induced by mechanical treatment occurs. For
this reason, it seems that the effect of cryomilling on the
physicochemical properties of APIs ought to be more
carefully studied.
MATERIALS AND METHODS
Materials
Furosemide (4-chloro-2-(furan-2-ylmethylamino)-5-
sulfamoylbenzoic acid, C12H11ClN2O5S, is a white crystal-
line powder. It was supplied by the Polpharma Pharma-
ceutical Works Poland and used without further
purification. The purity of the drug was declared by
supplier as being greater than 99%. The chemical structure
of the drug is shown in the inset in Fig. 1. For cogrinding,
polyvinylpyrrolidone (PVP) K30 (average molecular weight
40,000) and inulin (purity 99%) were used. Both materials
were supplied by the Polpharma Pharmaceutical Works
Poland.
Preparation Technique—Cryogrinding
of the Crystalline Material
The grinding was performed using a cryogenic impact mill
(6750 freezer/mill SPEX CertiPrep, Inc., USA) consisting
of a stainless steel vessel immersed in liquid nitrogen, within
which a stainless steel rod was vibrated by means of
magnetic coil. Before grinding, a 10-min precooling time
was programmed. Then, the mill was set at an impact
frequency of 15 cycles per second for 6-min grinding
periods separated by 3-min cool-down periods. The mass of
each sample was 1 g. Total milling times of furosemide
were 30, 60, 120 and 180 min. The powdered mixtures of
furosemide-PVP and furosemide-inulin were prepared at
1:1 mass ratios and cryomilled for 60 min.
After milling, the grinding vial was transferred to a
vacuum oven and allowed to warm to room temperature.
The freshly prepared cryomilled furosemide is a grey
powder with a slightly brown hue, intensified upon
increasing the milling time. Both furosemide-PVP and
furosemide-inulin mixtures after 60 min of cryomilling are
yellow powders. Expected humidity of the cryomilled
Fig. 1 Powder x-ray diffraction patterns (XRDP) starting from crystalline
furosemide (a), furosemide after 240-milling in a traditional ball mill
(pattern b) and after cryogrinding for 30, 60 and 120 min (respectively,
patterns c–e).
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samples was less than 4%. The ICP-AES analysis showed
that the iron content of a sample cryomilled for 180 min
sample was at a level matching that of a tap water. The
ground samples prepared in such a way were then analyzed
by the methods indicated below.
For the ball milling of furosemide at ambient tempera-
ture, a Planetary Ball Mill (Retsch) was used. A zirconium
jar was filled with 10 g of furosemide, and 6 balls (20 mm in
diameter) of the same material were added. The rotation
speed of 400 rpm was set. Each milling cycle lasted 15 min
and was followed by a 5-min break. The total milling times
were 240 min (4 h) and 1440 min (24 h).
X-ray Diffraction (XRD)
The X-ray diffraction experiment was performed at
ambient temperature on a Rigaku-Denki D/MAX RAPID
II-R diffractometr with a rotating anode AgKα tube (λ=
0.5608Å), an incident beam (002) graphite monochromator
and an image plate in the Debye-Scherrer geometry. The
pixel size was 100×100 μm. All samples were placed inside
Lindemann glass capillaries (2 mm in diameter). Measure-
ments were run with the sample filled and empty
capillaries, and the intensity of the empty capillary was
then subtracted. The beam width at the sample was
0.1 mm. The two-dimensional diffraction patterns were
converted into the one-dimensional intensity data using a
suitable software.
Differential Scanning Calorimetry (DSC)
DSC measurements were carried out using a Perkin Elmer
Pyris 1 DSC instrument (PerkinElmer Life And Analytical
Sciences, Massachusetts, USA) with liquid nitrogen cooling.
The instrument was calibrated for temperature and heat
flow using high-purity standards of indium. The sample
(m=0.00756 g) was placed in a sealed aluminium pan. The
thermogram was collected during heating of amorphous
furosemide prepared by cryomilling at a rate of 10°C/min
from −20°C to 190°C.
Test of Purity of Cryomilled Furosemide
and Chemical Stability in Solid State and Solutions
Ultra-Performance Liquid Chromatography (UPLC)
For the analysis of Furosemide and its degradation products
(impurities) a simple and sensitive chromatographic method
has been developed. The same method was used for
examination of the stability of the drug in the solid state
and solutions.
The analyses were performed using the Waters Acquity
UPLC system (Millford, MA, USA), equipped with a Binary
Solvent Manager, Sample Manager, Column Manager, and
Photodiode Array eλ Detector. Data acquisition and evalua-
tion were carried out using the Empower Pro 2 software
(Waters, Millford, MA, USA). A summary of the chromato-
graphic conditions is given in Table I. The LC separation was
achieved within a run time of 10 min.
Separation and Detection of Main Degradation
Product Formed During Cryomilling of Furosemide
High Performance Liquid Chromatography HPLC
The analysis was performed on an HPLC Beckman Gold
System (Beckman Coulter, Brea, CA, USA) instrument
using a thermostatted (30°C) Phenomenex C18 Luna
column (150×4.6 I.D. particle size 5 μm; 100Å). The
eluate was monitored at 230 nm. Total run time was
30 min with a flow rate of 0.5 ml/min. Acetonitrile and
acetic acid (0.1%) were filtered through a 0.45 μm
membrane filter and used as a mobile phase. First, an
isocratic flow (acetonitrile: acetic acid 20:80 v/v) was
Column: ACQUITY UPLC BEH C18 1.7 μm 2.1×150 mm (Waters, Wexford, Ireland)
Mobile phase A: 0.1% formic acid in water, pH adjusted to 5.6 with triethylamine
Mobile phase B: acetonitrile
Gradient program: start with 10% of mobile phase B
at 9.0 min 50% of mobile phase B
at 10.0 min 70% of mobile phase B
Flow rate: 0.3 ml/min
Column temp: 30°C
Injection volume: 1.0 μl
Injection mode: Partial Loop with Needle Overfill
Detection wavelength: 270 nm
Data collection rate: 40 points/s
Table I Chromatographic
Conditions (UPLC)
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applied. After 10 min the composition of the mobile phase
was changed gradually up to 80% acetonitrile: 20% acetic
acid, which was maintained for the last 10 min.
LC/MS Analysis
LC/MS system consisted of an Agilent 1100 series LC
system (Agilent Technologies, Santa Clara, CA, USA),
interfaced with MS-Bruker Daltonics HCTultra with a
turbo electrospray ionization detector (ESI). C18, Phe-
nomenex C18 Luna column (150×4.6 I.D. particle size
5 μm; 100Å) was used to determine sample degradation
products. Furosemide samples were dissolved in acetoni-
trile, and the solution was introduced into the ESI source
by continuous infusion using a syringe pump at a flow rate
of 0.5 ml/min. The ESI source was operated at 4 kV (in
positive and negative polarization), with the capillary
heater at 350°C and sheath gas pressure of 30 psi. Mass
spectra in the negative and positive ion modes were
acquired over the range m/z 50–500. The LC experi-
ments were carried out in the same conditions as by
HPLC method.
Preparative Separation by High Performance Liquid
Chromatography (HPLC)
The separation was carried out with Kontron Instruments
(Milan, Italy) using a thermostated (25°C) Phenomenex C18
Columbus column (250×10.00 I.D. particle size 5 μm; 100
Å) to separate impurity from waste fractions. Detection
wavelength was 230 nm. The elution conditions were a
linear gradient of acetonitrile and 0.1% trifluoroacetic acid
(5–40% of acetonitrile) in 60 min with a flow rate of
4.0 ml/min. After 60 min the composition of the mobile
phase was changed gradually up to 90% acetonitrile for the
last 15 min.
Matrix Assisted Laser Desorption Ionization-Time of Flight
(MALDI-TOF-MS) MS Mass Spectrometry
The MALDI-TOF mass spectra ware recorded on a Bruker
Biflex III (MA, USA) instrument in a reflector mode. The
ion source was set to 19.0 kV with the lens and reflector
voltage of 9.6 kV and 20.0 kV, respectively. For the
analysis, the DHB (2,5-dihydrobezoic acid) matrix was
used. Laser excitation was at 337.1 nm with 27%
attenuation.
Proton Nuclear Magnetic Resonance (1H NMR) Spectroscopy
The freeze-dried sample, collected after preparative sepa-
ration by means of HPLC, was diluted in DMSO solvent.
1H NMR spectrum was registered on a Varian Mercury
400 MHz spectrometer. The acquisition time and delay
times were 2 and 1 s, respectively.
RESULTS AND DISCUSSION
Physical Characterization of Cryomilled Furosemide
Figure 1a shows the X-ray diffraction pattern of the intact,
non-milled furosemide, which was taken at room temper-
ature and used as a reference. The sharp and highly intense
Bragg’s peaks confirmed crystalline nature of the drug. The
diffraction patterns presented in Fig. 1c–e correspond
respectively to the samples after 30, 60 and 120 min of
cryogrinding. In those samples, a strong reduction of
crystallinity proceeds with increasing milling time, resulting
in a considerable decrease of diffraction peaks. As illustrat-
ed in Fig. 1c, significant broadening and decrease of peak
intensities appeared just after 30 min of cryomilling. For
this sample, the degree of crystallinity (calculated as a ratio
of X-ray diffraction peaks areas for partially crystalline
sample to that being 100% crystalline) was found to be
12%. After 60 min of cryomilling, furosemide becomes
almost completely amorphous (degree of crystallinity 2%).
Complete conversion crystalline-amorphous furosemide
was noticed after 70 min (data not shown). The diffraction
patterns recorded at room temperature for samples
cryomilled for 120 and 180 min revealed absence of
Bragg’s peaks, which were replaced by halo patterns
(calculated degree of crystallinity 0%), being a characteristic
feature of materials having no long-range three-
dimensional molecular order, i.e amorphous one.
As frequently reported in the literature, transforma-
tion of a crystalline material to a completely disordered
one caused by mechanical milling occurs only at temper-
atures much lower than the glass transition temperature,
Tg, of corresponding supercooled liquid (11). This
explains why the crystalline-amorphous powder transfor-
mation takes place more readily at a lower temperature. It
is worth pointing out that the reduction of the milling
temperature brings the same effect as the increase in
milling intensity. Hence, by cryomilling it is possible to
reduce time required for considerable particle size
reduction and to avoid extremely long milling times to
get the same effect as in a traditional ambient-temperature
device. To illustrate the lower efficiency in production of
amorphous materials by mechanical milling carried out at
room temperature, the grinding process of FUR was also
performed in a traditional ball mill (milling intensity Ω=
400 rpm). In Fig. 1b the XRD patterns of a sample
ground for 240 min at ambient conditions are shown.
Certainly, reduction of peak intensities indicating a
decrease in grain size and distortion of crystalline lattice
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was observed (degree of crystallinity 31%), but this effect is
not as significant as in the case of milling carried out at
liquid nitrogen temperature. This finding agrees with
results reported for other systems like those of indometh-
acin or trehalose. For the former, amorphous state was
reached only after 60 min of cryogrinding (13), while
during mechanical treatment at room temperature more
than 1200 min (9) are required to get a similar effect.
Similarly, complete amorphization of trehalose in the
traditional ball mill was reached even after 1380 min of
grinding (10).
It should also be noted that Villiers and Tiedt (28) have
found that prolonged milling of furosemide in a traditional
ball mill resulted in a practical limit in particle size
reduction within a relatively short time (30 min). Indeed,
even after 1440 min of milling in the conventional device
the degree of crystallinity was estimated to be greater than
25%. Our results indicate that in the high-impact cryogenic
device we are able to effectively reduce the particle size to a
level probably hardly attainable during room temperature
treatment.
As already mentioned in the Introduction, solid-state
amorphization of pharmaceuticals is a very problematic
issue, and several concepts were proposed. Some of them
suggest that the process of amorphization occurring during
mechanical treatment in a mill cannot be regarded as glass
transition in the traditional sense (15). However, the
presence of the glass transition event can be detected by
monitoring the change of thermodynamic variables such as
heat capacity. In Fig. 2 we present a DSC thermogram
recorded upon heating (10°C/min) of a sample cryomilled
for 180 min. Within the examined temperature range, two
thermal events were observed: the glass transition at 55°C
(calculated as a midpoint of the glass transition step)
followed by recrystallization at 74°C. Thus, characteristic
for the glass transition, jump in the heat capacity really
occurred. This means that the drug can certainly reach the
glassy state upon cryogrinding. The exothermic peak
around Tc=74°C was ascribed to recrystallization of the
cryomilled sample. Such a thermal behavior is often
observed in the case of ground samples.
Next, time-dependent XRD measurements at room
temperature and 10% RH were carried out to test physical
stability of the amorphous furosemide prepared by cryomil-
ling. In Fig. 3 we present diffraction patterns recorded at
specified time intervals. As the storage time increases,
initially amorphous furosemide tends towards a more stable
crystalline form. This is visible as an increase in Bragg’s
peaks intensities. However, between 3 and 21 days of
storage, the degree of crystallinity does not significantly
increase and maintains at an almost constant value of 6%.
The slowing down of the crystallization progress is quite
often observed with cryomilled samples. For example, when
the degree of crystallinity of the initially amorphous
cryomilled ziprasidone base and ziprasidone hydrochloride
reached 30% and 37%, respectively (that happened after
2 weeks of storage at room temperature), no significant
changes in the crystallization progress were observed later
on (29).
We claim that the degree of crystallinity remains
constant at 6% because of our specific storage conditions.
Crystallization of cryomilled furosemide was monitored
after placing it into the Lindemann glass capillary of 2 mm
Fig. 2 DSC thermogram recorded upon heating (10°C/min) of
furosemide cryomilled for 180 min.
Fig. 3 Changes in the X-ray diffraction patterns of furosemide cryomilled
for 60 min and stored at 25°C and 10% RH.
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in diameter. Throughout the whole study, cryomilled
materials stayed in that capillary, with access to fresh air.
We suppose that when different storage conditions were
adopted during monitoring the degree of crystallinity, the
stability of cryomilled furosemide might be completely
different. For example, when the samples were exposed to
greater RH conditions or we provided the greater free
surface, the crystal growth might be orders of magnitude
faster.
Chemical Instability of Cryomilled Furosemide
As mentioned in the Introduction, due to its poor solubility
and bioavailability, crystalline furosemide is a challenging
molecule for the pharmaceutical industry. Still more so,
furosemide has been known to be unstable during adverse
storage conditions. It undergoes acid-catalyzed hydrolysis in
water solutions, photochemical degradation in the solid
state and thermal decomposition at a melting point. In all
three cases, the same degradation product is formed,
namely 4-chloro-5-sulfamoylanthranilic acid (CSA)
(23,30). As reported, both furosemide and its main
degradation product possess toxic potentials (31) and might
undergo further photodechlorination to N-furfuryl-5-sulfa-
moylanthranilic acid (FSA) (32). For this reason, it seems
that the crystalline furosemide itself is strongly susceptible to
degradation when exposed to inappropriate storage or
manufacture conditions.
The milling procedure of furosemide was carried out at
liquid nitrogen temperature where, as suggested, no
chemical degradation of the milled material should occur.
Still more so, some of our previous studies concerning
amorphous pharmaceuticals (like telmisartan or ziprasi-
done) formed by cryomilling have clearly demonstrated that
the amount of impurities formed during that type of
mechanical treatment varies (irrespective of the milling
time) only from 0.2% to 0.5% (29,33). This certainly
implies that cryomilling seems to be a really safe method of
solid-state amorphization.
To check whether this is also true for the drug under
study, we used the ultra performance liquid chromatogra-
phy (UPLC) technique, as an infallible tool in the purity
analysis of active substances and their final dosage forms. A
chromatogram of the crystalline furosemide used for further
analysis as a reference is displayed in Fig. 4, as a black solid
line. As seen, it consists of one very well-pronounced peak
assigned to furosemide and the other, very small one with
the relative retention time of 0.26. The unknown impurity
assigned to this peak was denominated as Imp.1. The area
under the mother peak was found to be equal 99.95%.
After 30, 60, 120 and 180 min of effective cryomilling of
the furosemide (1 g each time), next UPLC chromatograms
Fig. 4 Overlaid chromatograms of crystalline furosemide (black) and that cryomilled for 30 min (navy blue), 60 min (green), 120 min (blue) and 180 min (purple).
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were recorded (Fig. 4, respective chromatograms as
indicated by arrows). It can be seen that with increasing
milling time, significant increment of the unknown Imp.1
assigned as the main degradation product was observed,
and several minor peaks arise as well. A comparison of
impurity profiles of the crystalline furosemide and that
cryomilled for different periods of time is given in Table II
and Fig. 5. Impurities below 0.05% are not reported. The
quantity of Imp.1 was closely related to the duration of the
cryomilling process, and when the substance was milled for
180 min it reached a level of 5.13%, while the total content
of all impurities formed during this time was 6.81%. To the
best of the authors’ knowledge, this particular behaviour of
furosemide is the first evidence directly showing that
cryomilling can be responsible for chemical degradation
of the drug. Nevertheless, to investigate this phenomenon
in more detail, it is necessary to perform additional
studies.
From the literature, it is known that by preparing solid
dispersion it is possible to improve physical and chemical
stability of amorphous systems (34). One of the methods
which can be used to prepare solid dispersion is co-grinding
with specially selected excipients such as polyvinylpyrroli-
done (PVP) or polysaccharides. Polymer carriers or saccha-
ride derivatives are likely to form amorphous solid
solutions. Moreover, they usually have high melting and
glass transition points so that their addition to the solid
dispersion mixture increases its overall glass transition
temperature Tg. Consequently, a considerable decrease in
molecular mobility responsible for crystallization tendency
and chemical reactivity of amorphous systems can be
attained. As believed, the improvement of stability of
amorphous mixtures resulted from specific interaction
excipient—drug and formation of molecular alloys. Besides,
more than 20 years ago, Doherty and Perk revealed that
PVP tends to form hydrogen bond with furosemide in solid
dispersion, which may account for its stabilization (35,36).
Hence, in order to check whether it is possible to prevent
chemical degradation of furosemide upon cryomilling, co-
grinding has been performed. The mixtures of furosemide-
PVP and furosemide-inulin (in weight ratios of 1:1 each)
were submitted to mechanical treatment at liquid nitrogen
conditions. After 60 min of cryomilling, a complete
amorphization of both mixtures was proven by X-ray
Table II Comparison of the Impurity Levels Formed During Cryomilling of Furosemide
Analyte label Relative retention
time
Furosemide
Crystalline Cryomilled for 30 min Cryomilled for 60 min Cryomilled for 120 min Cryomilled for 180 min
Amount of analyte [%]
imp. 1 0.26 0.05 0.70 1.68 4.50 5.13
imp. 2 0.35 – – 0.06 0.06 0.07
imp. 3 0.76 – – – – –
imp. 4 0.85 – – – 0.13 0.14
imp. 5 0.92 – – 0.06 0.13 0.14
Furosemide 1.00 99.95 99.20 97.82 94.02 93.19
imp. 6 1.10 – – – – –
imp. 7 1.40 – – 0.06 0.17 0.21
imp. 8 1.42 – 0.10 0.23 0.58 0.66
imp. 9 1.49 – – – 0.10 0.12
imp. 10 1.64 – – 0.09 0.31 0.34
Total impurities Total impurities Total impurities Total impurities Total impurities
0.05 0.80 2.18 5.98 6.81
Fig. 5 Comparison of furosemide impurity profiles in relation to the
duration of the cryomilling process.
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diffractograms (not shown herein). Next, the purity of the
outcome materials was tested by UPLC technique. The
chromatograms are presented in Fig. 6, and a comparison
of the impurities profile is given in Table III (impurities
below 0.05% are not reported). Similarly to furosemide
cryomilled alone, in the co-ground furosemide-PVP and
furosemide-inulin mixtures, several impurities were
detected. Remarkably, a significant increase in the amount
of Imp.1 with relative retention time of 0.26 was reported
(respectively, 3.44% and 5.17% for furosemide-inulin and
furosemide-inulin mixtures). Again, as a consequence of
cryogenic mechanical treatment, the purity of the systems is
substandard. Based on the above results, we can conclude
that grinding of the furosemide with the selected polymer
or polysaccharide for a studied weight ratio won’t bring
chemical stabilization of studied pharmaceutical. The
Fig. 6 Overlaid chromatograms of crystalline furosemide (black) and that cryomilled alone for 60 min (blue), with inulin (navy blue) and with PVP (green).
Table III Comparison of Impurity Profiles of Furosemide Prepared in Different Ways
Analyte label Relative retention
time
Furosemide crystalline Furosemide (cryomilled
for 60 min)
Furosemide cryomilled
with inulin 1:1 ratio
Furosemide cryomilled
with PVP 1:1 ratio
Amount of analyte [%]
imp. 1 0.26 0.05 1.68 3.44 5.17
imp. 2 0.35 – 0.06 0.19 0.26
imp. 3 0.76 – – 0.06 0.06
imp. 4 0.85 – – – 0.16
imp. 5 0.92 – 0.06 0.12 0.07
Furosemide 1.00 99.95 97.82 95.69 93.92
imp. 6 1.10 – – 0.05 0.08
imp. 7 1.40 – 0.06 0.05 –
imp. 8 1.42 – 0.23 0.25 0.08
imp. 9 1.49 – – – –
imp. 10 1.64 – 0.09 0.15 0.20
Total impurities Total impurities Total impurities Total impurities
0.05 2.18 4.31 6.08
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results of our studies are in a complete opposition to
Doherty and Perk’s findings, who claimed that no chemical
degradation was found in any of their solid solutions (36).
However, to prepare amorphous solid dispersions they have
chosen a solvent method, in which amorphization mecha-
nism is completely different than that of milling. It is also
worth pointing out that they have prepared their solid
dispersions in very mild conditions where no degradation
occurred (T=50°C). On the other hand, by carrying out
the cryomilling experiment, we have exposed furosemide
on extreme conditions and provided at the same time high-
energy to the system. In addition, application of mechanical
force might lower activation barrier for the chemical
reaction to occur. This issue will be discussed later in this
paper.
The worsening of chemical stability of furosemide when
ground with PVP and inulin as compared to when it was
milled on its own is another quite surprising result. Our
preliminary measurements indicate that greater chemical
instability of cryomilled furosemide-PVP and furosemide-
inulin solid solutions might be related to the formation of a
hydrogen bonding between furosemide and excipient
creating the possibility of proton migration across hydrogen
bond. Interestingly, application of non-hydrogen bonding
matrices improves significantly the chemical stability of
cryomilled furosemide, but more detailed studies will be
given elsewhere.
To identify the main degradation product formed upon
cryomilling (Imp.1), the mass spectrometry and Nuclear
Magnetic Resonance techniques have been used. First, the
liquid chromatography/mass spectroscopy technique (LC/
MS) was chosen, since it enables not only physical
separation of individual impurities, but also can provide
valuable information about the molecular weight, structure
and/or quantity of a sample. The chromatogram was
registered using a PDA detector and a mass spectrometer.
The first detection showed the presence of Imp.1 in the
eight minute of HPLC analysis (data not shown), but in the
mass spectrum the corresponding peak was missing. This
could be due to poor ionizability of the unidentified Imp.1
by means of Electrospray Ionization (ESI) technique (see
Fig. 7a). Nevertheless, from the recorded mass spectrum we
can initially accept the molecular weight of the unknown
degradation product formed upon cryomilling as 250.1
daltons. This is confirmed by the presence of [M+H]+ ion
of m/z 251.1 (Fig. 7b). However, to be sure that 250.1 is
the exact mass of the unknown Imp. 1, another ionization
technique was used. At first, preparative separation of it
from the waste fractions was carried out using LC
technique. Thus, a fraction containing Imp.1 was isolated
and lyophilized. Next, the Matrix Assisted Laser Desorption
Ionization-Time Of Flight Mass Spectrometry (MALDI-
TOF-MS) was used to establish the mass weight of the
impurity. This technique was employed mainly owing to its
slightly different ionization mechanism. As a MALDI
matrix, 2,5-dihydroxybenzoic acid (DHB) was used. In
Fig. 7c, a positive-ion MALDI-TOF mass spectrum of the
main degradation product formed during cryomilling is
presented. The single peak with a m/z ratio of 176.9
corresponds to a signal from the DHB matrix with an Na+
adduct. Two very well-shaped signals with m/z ratios of
273.0 and 288.3 correspond respectively to the Na+ and
K+ adducts of the unknown impurity of molecular weight
250 u. Consequently, the MS analysis has provided reliable
information about the most probable molecular weight of
the unidentified impurity. However, to avoid any specula-
tion concerning determination of the chemical structure of
Imp.1, the 1H NMR spectroscopy was employed. A 400-
MHz 1H NMR spectrum of Imp.1 recorded at 30°C
covering the range of 0.5 to 9.5 ppm is shown in Fig. 8. As
seen in the 1H spectrum, except the peak of the DMSO
solvent (a singlet at 2.5 ppm, labeled as A), the other three
peaks appear at 6.9 ppm (B), 7.2 ppm (C), 8.3 ppm (D).
These 1H chemical shifts were compared with those in the
1H NMR spectrum already known for crystalline furose-
mide (37). Single and sharp signals at 6.9 ppm and 8.3 ppm
were assigned to two aromatic protons, while the single and
broad peak at 7.2 ppm was ascribed to sulfonamide NH2.
As being distinct from the spectrum of crystalline furose-
mide, in that of the unknown Imp. 1, there is no response
from protons of the furan ring (6.35 ppm, 6.4 ppm and
7.6 ppm (37), aromatic -NH proton (8.6 ppm (37)), and that
arising from the CH2 group (4.5 ppm (37)). Based on these
results, we have concluded that the most probable
degradation product formed upon cryomilling of furose-
mide is 4-chloro-5-sulfamoylanthranilic acid (CSA) with
molecular weight equal to 250 u. It should also be noted
here that an identical 1HNMR spectrum has been reported
for a thermal decomposition product of furosemide (38).
The chemical structure of CSA is drawn in the inset in
Fig. 8b.
The fact that the main degradation product of high-
impact cryomilling of furosemide is exactly the same
compound as that formed due to thermal decomposition
suggests that during extensive mechanical cryomilling, the
temperature locally increases in an uncontrollable way so
that amorphization occurs due to thermal melting followed
by quenching. However, between each cycle, cool-down
periods were programmed so that the heat of reaction was
repeatedly removed and a low temperature environment
was maintained. Still more so, the melting point of
furosemide is >200°C, while the milling was carried out
at a liquid nitrogen temperature (−196°C). For this reason,
local growth of temperature caused by mechanical treat-
ment and resulting in melting with decomposition of
furosemide is actually unlikely to happen. Moreover,
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Decamps et al. have shown that such a scenario even in the
case of a material ground at room temperature is fairly
impossible (10,11). The absence of mutarotation and
carmelization process in cyclic sugars submitted to extensive
grinding was proven by the presence of only an α-anomeric
form in the milled material, while if the melting really had
occurred, transformation from α- to β- pyranose would
have been observed.
Fig. 7 (a) Positive LC-MS full spectrum of a furosemide sample after cryomilling, (b) positive MS spectrum at the 8th minute of analysis (retention time of
the main degradation product formed upon cryomilling), (c) MALDI-TOF MS spectra of the isolated Imp.1 (main degradation product formed upon
cryomilling).
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It has been well established that micronized drugs,
partially as well as completely amorphous, have an
extensive surface area, and for this reason uncontrolled
chemical reactions are likely to proceed more quickly as
compared to their crystalline counterparts. The rapid
growth of chemical reactivity in the amorphous region is
often linked to an increasing level of molecular mobility or
moisture content (7). It can thus be hypothesized that the
increment of Imp.1 observed upon increasing milling time
is related to enhanced chemical reactivity of the amorphous
material rather than to any negative effect caused by high-
impact milling process itself. To clarify that hypothesis,
chemical stability of amorphous furosemide prepared by
cryomilling in the solid state and in solution was investigated.
Fig. 8 (a) The 1HNMR spec-
trum of the main degradation
product formed upon cryomilling
panel (b) enlarged region from
6.8 ppm to 8.6 ppm.
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The kinetics of the buildup of Imp. 1(CSA) was monitored by
UPLC technique. The solid-state degradation study of the
cryomilled furosemide extended up to 6 months. As has been
found, in a cryomilled powder (one cryomilled for 180 min)
stored at room temperature for 6 months, an increase in the
main degradation product within that period was less than
0.5% (data not shown herein). Thus, the degradation in the
solid state certainly proceeds, but not fast enough to be the
reason of a sudden growth of Imp.1 upon cryomilling. It was
also found that in organic solvents, such as methanol, the
cryomilled drug is quite stable (no significant increment in the
impurity level was noticed), while in acidic solutions furose-
mide underwent acid-catalyzed hydrolysis. In this condition,
the linear upturn of Imp. 1 (sample milled 60 min) within
12000 min was monitored. The results are shown in Figs. 9
and 10 (in the latter, only the first 4200 min are shown). As
the hydrolysis progressed, a significant growth of the main
impurity was observed. This indicates that the cryomilled
furosemide is very unstable at lower pH values, and similarly
to crystalline one, CSA is expected to be the main
degradation product. It is worth emphasizing that the
growth of Imp.1 from 1.68% to ~6% required approxi-
mately 3600 min in acidic solution, while the same effect was
attained after just 180 min of cryomilling. This implies that
chemical degradation induced and proceeding in the high-
energy milling has a surprisingly high rate.
For comparison, acid-catalyzed hydrolysis of crystalline
furosemide in water solution was carried out. The results in
acidic medium are presented in the inset of Fig. 10. We
Fig. 10 Buildup of the impurity with relative retention time of 0.26
(Imp.1) in acidic solution.
Imp.1 Furosemide
Fig. 9 Increment of Imp.1 in acidic environment for cryomilled furosemide (the sample cryomilled for 60 min).
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have found that within just the first 960 min (~16 h), the
degradation rate of the cryomilled material was roughly
about two times higher than that of the crystalline one. As a
matter of fact, the cryomilled furosemide undergoes more
rapidly acid hydrolysis, and its chemical reactivity is
certainly greater than that of the crystalline substance.
However, this argument cannot be considered as the
dominant reason for the chemical degradation of the
cryoground material. Moreover, if degradation of furose-
mide were only the result of amorphization (i.e. the
amorphous form of cryomilled furosemide were so meta-
stable that it decomposed immediately after being formed),
after the complete transformation crystalline to amorphous
solid, we shouldn’t observe any differences in the total
impurities amount for all the cryomilled and amorphous
samples.
At this point, it should also be noted that up to the
present, there are no reports in the pharmaceutical
literature clearly showing that cryomilling, as a mechanical
process of particle size reduction, might activate and aid
chemical degradation of pharmaceuticals. However, the
fact that the prolonged high-energy milling can trigger not
only structural changes, but also can activate and signifi-
cantly accelerate chemical process is nothing new. This type
of reaction is well-known and recognized as mechanochem-
ical processes. Mechanochemical reactions have very
interesting applications, especially in inorganic synthesis
(39,40). For example, by ball milling, transition metals such
as Ni or Co and their oxides can be synthesized.
Furthermore, mechanically activated chemical reactions
allowed production of semiconductors, alloys or spinels
with no need of high temperature conditions required to
initiate them otherwise. Originally, chemical processes
taking place during mechanical treatment were ascribed
to the mechanical energy generated and converted into
local heat. However, the resulting products of melting and
mechanically initiated reactions might be completely
different (40). For this reason, chemical processes occurring
in the mill cannot be identified only with an increase in
temperature even up to the melting point. Interestingly,
in organic chemistry these types of reactions are less
likely to proceed and are practically absent. Some signs
of chemical transformations caused by mechanical mill-
ing were reported for the drug piroxicam (18). In that
case, proton transfer (tautomerisation) accompanied solid-
state amorphization.
In newly designed high-energy mills the impact generated
during the grinding process might be orders of magnitude
greater than that achieved in traditional devices. Thus,
obviously not only particles sizes can be reduced much faster
and easier, but also some chemical reactions which probably
would never be accessible by traditional milling can be
activated therein. Mechanical milling facilitates chemical
reactions due to the randomness of the flattening process.
This provides (as grain size decreases) repeatedly new reaction
interface. Moreover, at cryogenic temperature, pharmaceuti-
cal materials become hard and brittle. Since mechanical
treatment of a substance in the mill creates a great amount of
stress, such material is obviously more susceptible to any
physical and chemical changes. Bearing in mind the above, it
is obvious that the milling device must be treated in any
circumstances as a chemical reactor where under favourable
conditions chemical processes can be mechanically provoked.
It is also worth mentioning that in contrast to typical
thermochemical reactions, for chemical reactions initiated
and promoted by high-impact mechanical treatment, a
considerably lower activation energy is required. For exam-
ple, the activation energy of thermochemical reaction of iron
oxide formation was found to be 54 kJ/mol, while the same
reaction caused by mechanical treatment required only
0.7 kJ/mol (40).
Rarely have any thermally activated chemical reactions
taken place at a very low temperature; if so, it involves
mostly inorganic compounds. The rate of thermochemical
reaction strongly depends on the temperature and usually
increases with increasing temperature. Thus, in the case of
cryogenic grinding of furosemide, thermally activated
chemical decomposition is simply impossible. On the other
hand, the energy required for releasing the mechanochem-
ical reactions is applied to the solid state through
mechanical process, not thermally. This would explain
why decomposition occurs during high-energy milling even
at liquid nitrogen temperature.
Furthermore, the degradation pathway of crystalline and
amorphous furosemide in solid state as well as in aqueous
solution involves formation of CSA. Conversion of furose-
mide to CSA proceeds by cleavage of the C-N bond (see
Scheme 1). As reported by Beyers et al., the experimentally
measured activation energy for thermal decomposition of
furosemide is 47.7 kcal/mol, while typically the energy
barrier for C-N bond cleavage is about 59 kcal/mol (38). As
they speculated in the case of furosemide, the weakening of
the C-N bond is the consequence of negative inductive
effect of the furan ring on the one hand and delocalization
Scheme 1 Degradation pathway of the cryomilled furosemide.
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of electrons of the aniline nitrogen in the chlorosulfoamyl
benzoic acid entity on the other hand (38). It is worth
noting that whether one deals with either amorphous or
crystalline furosemide in the solid or solution, formation of
CSA is always preferable than any other option.
During the high-impact cryogenic grinding, furose-
mide was prone to decompose to CSA. In other words,
the cryogrinding provided enough mechanical energy to
initiate chemical reaction. Unfortunately, there is no
possible experimental way to verify the amount of
mechanical energy that was generated and transferred
to the ground sample during mechanical treatment under
cryogenic conditions. However, based on some very
rudimentary theoretical consideration proposed by
Delogu et al. (41), we are able to estimate the mechanical
energy dose transferred to a sample, i.e. total energy
transfer mechanically transferred to the powder over a
definite milling time. Of course, this is only an estimation
which does not include the effect of cryogenic temperature
upon the milling process. On the other hand, it predicts
the potential impact of that mechanical device. In the first
step, it is necessary to describe the trajectory of the
magnetic rod placed in the grinding vessel and vibrated
between two poles of an electromagnet. This trajectory is
presented in Scheme 2. In our case, it is rather an easy-to-
guess path; however, for a cylindrical-shaped traditional
ball mill with few balls inside, it might be slightly more
complicated (42).
By assuming a purely plastic collision, the impact energy
generated per hit can be calculated from the following
equation:
E ¼ mRv
2
2
ð1Þ
where mR is the mass of the magnetic rod and v is its
velocity. The latter can be calculated knowing specific
milling configuration and size of the vessel. The impact
energy was found to be E=1.5 mJ/hit. From impact energy
E and frequency N generated per hit, the milling intensity
can be determined as (41)
I ¼ E  N ð2Þ
This leads to I=22 mW. The total energy transferred to the
powder, known also as the specific milling dose, is given by
(41)
Dm ¼ E  N  tmp ð3Þ
where mp is the mass of the powder and t refers to the total
milling time. Assuming the total mass of the powder as 1 g,
our consideration leads to the following values: 6.5, 12.5,
and 18.7 kcal/mol for 60, 120 and 180 min of grinding,
respectively These values are obviously not high enough to
cause decomposition of the drug upon milling, especially
because the cryogenic temperature effect was not taken into
account. However, one should be aware that during milling
the collisions are more likely heterogeneous rather than
homogenous. Thus, the energy transfer to each particle
wouldn’t be the same. Some of them would receive it more,
while others less, and only those entities which received
enough energy to overcome activation barrier would be
decomposed. As revealed by UPLC studies, just 2.18%,
5.98% and 6.81% out of 1 g of furosemide sample
decompose after, respectively, 60, 120 and 180 min of
milling. If the specific milling dose is calculated for only
such amounts of the powder (according to their total milling
time), we obtain that in each case the energy transferred to
the samples exceeds more than 200 kcal/mol. These
theoretical estimations indicate that the milling is able to
generate enough energy to overcome the energy barrier
and initiate decomposition of furosemide. However, exper-
imental values of total energy transferred to the sample
would certainly be lower. We suppose that as the particle
Scheme 2 Typical vessel used
for high-impact cryogenic grinding.
3234 Adrjanowicz et al.
size decreases and the transformation of crystalline drug to
amorphous one is attained, mechanically activated degra-
dation of furosemide would speed up due to increased
surface area of the cryoground material and its enhanced
chemical reactivity.
Finally, it should be also noted that the UPLC analysis
of furosemide ball-milled at room temperature for
1440 min revealed total impurity level less than 0.6%
(data not shown in this paper). Accordingly, we think
that there must be a relationship between full amorph-
ization of furosemide and acceleration of its degradation.
Since we are not able to completely amorphize furose-
mide in the ball-mill, just small amounts of impurities
were found in that sample. Only by performing the
cryogenic experiment we are able to monitor the
degradation of furosemide, because only this high-
impact device is able to provide enough mechanical
energy for full amorphization of the material. We also
conjecture that in a region very close to complete
amorphization and just above that point, this process
proceeds at a maximum rate. In our opinion, the fact
that the decomposition proceeds faster between time
intervals of 30–60 min and 60–120 min and slower
between 120 and 180 min (see Fig. 5 or Table I) indicates
that this reaction has slowly reached a saturation point,
and longer mechanical treatment won’t change anything.
CONCLUSIONS
Cryomilling of a crystalline powder is becoming a very
popular way of micronization as well as amorphization. Since
the milling takes place at a liquid nitrogen temperature, it is
possible to effectively reduce particle size within a relatively
shorter time and, as believed, to prevent local heating.
Mechanical milling of pharmaceuticals offers a lot of
advantages, especially in the context of solubility and
bioavailability improvement. The high-impact cryomilling
enables production of completely amorphous materials that
otherwise could not be obtained during the room temperature
ball-milling. However, current studies revealed that in some
circumstances it can activate and accelerate not only structural
changes (solid state amorphization) but also chemical decom-
position of drug. For this reason, more attention should be
paid to controlling the purity of the starting cryoground
materials.
The examined herein drug substance, furosemide, was
found to be physically and chemically unstable after extensive
cryomilling. The chemical decomposition of the mother
material was found to be directly correlated with the duration
of the cryomilling process. Degradation of furosemide that
proceeds upon cryogenic grinding is most probably initiated in
the vicinity of the amorphization region, since amorphous
materials are known for their greater chemical reactivity, and
in opposition to crystalline counterparts, they are more
susceptible to any unwanted chemical changes. Acid-
catalyzed hydrolysis of the cryoground amorphous sample
proceeds at an almost twice greater pace than that of the
crystalline drug. It is a clear sign of intensified chemical
reactivity of the amorphous material in solution. During long-
term storage of the cryomilled material in the solid state at
ambient conditions, the degradation proceeds, albeit much
slower. However, most surprising is its acceleration provoked
by the high-impact mechanical treatment. Only after 180 min
of cryomilling, the increment of Imp.1 (CSA) reached the same
value as that found in the acid solution after dozen of hours. It
is worthwhile to note that in a low pH medium the rate of
hydrolysis is reported to be the highest. This attracts our
attention to an enormous potential of the high-impact device,
creating a favourable environment for various reactions
activated mechanically to arise, with no need of any solvents.
The degradation pathway of furosemide in the solid state
and solution involves formation of the same product, CSA.
The lower activation barrier required for such transformation
is probably the direct consequence of weakening of the C-N
bond and can be overcome by providing enough mechanical
energy during the crashing process. Mechanical milling, due to
randomness of each collision provides repeatedly new reaction
interface and facilitates decomposition of the compound.
Since chemical reaction activated by mechanical treatment
does not need a thermal factor to begin, decomposition of
furosemide is likely to proceed even at a liquid nitrogen
temperature. The scenario which assumes local heating in the
milling device, causing melting and thermal decomposition of
furosemide, is less likely to happen, especially because of the
temperature at which the milling is performed.
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